RETA - Reata Pharmaceuticals, Inc.
| Previous Close | 173.19 |
| Open | 171.55 |
| Bid | 184.67 x 1000 |
| Ask | 186.95 x 800 |
| Day's Range | 171.55 - 185.46 |
| 52 Week Range | 47.50 - 185.52 |
| Volume | 1,259,171 |
| Avg. Volume | 382,054 |
| Market Cap | 5.567B |
| Beta (3Y Monthly) | 2.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.06 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 210.75 |
- Zacks
Reata (RETA) Jumps: Stock Rises 5. 6%
Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Benzinga
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
- TheStreet.com
Riding 2 Big Winners in Small Biotech
Reata Pharmaceuticals and Axsome Therapeutics each have had a terrific 2019, which helps offset the losing bets in this high-beta sector of the market.
- Zacks
Reata Successfully Completes Neuromuscular Disorder Study
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
- Investor's Business Daily
How A Recently Reacquired Drug Added $1.8 Billion To This Biotech's Value
Reata Pharmaceuticals soared early Tuesday on positive Phase 2 test results of a treatment for Friedreich's ataxia. The biotech recently reacquired omaveloxolone from AbbVie.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For October 15, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Synthesis Energy Systems (NASDAQ: SES ) shares ...
- Schaeffer's Investment Research
Reata Pharmaceuticals Options Hot as Shares Skyrocket
The firm's omaveloxolone drug met the main goal of a mid-stage study
- Benzinga
The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
- MarketWatch
Reata stock jumps 30% as neuromuscular disorder drug meets study endpoint
Reata Pharmaceuticals Inc. shares surged after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment. Reata shares, which had been halted after hours, surged 33% in the extended session, after closing up 5% at $100.59 in Monday trading for a market cap of just over $3 billion. Compared to placebo, the company said a mid-stage study of its treatment omaveloxolone significantly improved symptoms of Friedreich's ataxia, a debilitating neuromuscular disease that results in loss of coordination, weakness and fatigue. There are currently no treatments approved by the Food and Drug Administration for the disease, which affects about 22,000 globally, the company said.
- GlobeNewswire
Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR.
- TheStreet.com
[video]Reata Shares Jump on Drug-Study Results
Stock gains in after-hours trading after phase II test results meet primary endpoint for a treatment of a rare genetic disease.
- GlobeNewswire
Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019
IRVING, Texas, Oct. 11, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting.
- Investor's Business Daily
Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs
Reata Pharmaceuticals stock jumped Thursday after the biotech company reacquired the rights to several important drugs from pharmaceutical giant AbbVie. Two drugs are in pivotal studies.
- Benzinga
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...
- GlobeNewswire
Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie, Inc. (AbbVie) for territories outside of the United States with respect to bardoxolone methyl (bardoxolone) and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators. As a result, Reata now possesses exclusive, worldwide rights to develop, manufacture and commercialize bardoxolone methyl (bardoxolone), omaveloxolone, and all other next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone which are licensed to Kyowa Kirin Co., Ltd.
- Simply Wall St.
Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Pay Fair?
We wouldn't blame Reata Pharmaceuticals, Inc. (NASDAQ:RETA) shareholders if they were a little worried about the fact...
- Zacks
Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock?
Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.
- Simply Wall St.
Is Reata Pharmaceuticals (NASDAQ:RETA) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Thomson Reuters StreetEvents
Edited Transcript of RETA earnings conference call or presentation 8-Aug-19 12:00pm GMT
Q2 2019 Reata Pharmaceuticals Inc Earnings Call
- Benzinga
The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 28) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down ...
- GlobeNewswire
Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Manmeet S. Soni as Chief Financial Officer (CFO) and Executive Vice President, effective August 28, 2019. Mr. Soni will report to Reata’s Chief Executive Officer and President, Warren Huff, and will provide strategic leadership in the overall financial management of Reata. His responsibilities will include corporate finance and accounting, information technology, corporate strategy, corporate communications, and investor relations. Jason D. Wilson, who has been with Reata since 2006 and served as CFO, will assume a new role as Executive Vice President of Operations. Mr. Wilson will continue to report to the Chief Executive Officer and will oversee Reata’s operations, including program and clinical operations, manufacturing, bioinformatics, quality, global alliances, and human resources.
Motley FoolReata Pharmaceuticals, Inc. (RETA) Q2 2019 Earnings Call Transcript
RETA earnings call for the period ending June 30, 2019.
- Zacks
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.79% and 0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs
IRVING, Texas, Aug. 08, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter.
- Simply Wall St.
Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Paid At A Competitive Rate?
In 2002 J. Huff was appointed CEO of Reata Pharmaceuticals, Inc. (NASDAQ:RETA). This analysis aims first to contrast...
